Edwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem Sells 11,250 Shares

Edwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total transaction of $797,287.50. Following the completion of the transaction, the chief financial officer now directly owns 30,387 shares of the company’s stock, valued at $2,153,526.69. This trade represents a 27.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Edwards Lifesciences Price Performance

NYSE EW opened at $70.90 on Friday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.73. The stock has a market cap of $41.68 billion, a price-to-earnings ratio of 10.17, a PEG ratio of 4.82 and a beta of 1.12. The company’s 50 day moving average is $71.49 and its two-hundred day moving average is $70.49.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

EW has been the subject of several analyst reports. Barclays raised their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. The Goldman Sachs Group boosted their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Piper Sandler increased their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Royal Bank of Canada reissued an “outperform” rating and issued a $85.00 target price on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Finally, Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has an average rating of “Hold” and a consensus target price of $79.95.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors have recently added to or reduced their stakes in the stock. Avior Wealth Management LLC grew its stake in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares in the last quarter. Advisors Asset Management Inc. lifted its position in shares of Edwards Lifesciences by 7.7% in the third quarter. Advisors Asset Management Inc. now owns 11,856 shares of the medical research company’s stock worth $782,000 after buying an additional 852 shares in the last quarter. Eagle Asset Management Inc. boosted its stake in Edwards Lifesciences by 38.0% during the third quarter. Eagle Asset Management Inc. now owns 30,282 shares of the medical research company’s stock valued at $2,006,000 after buying an additional 8,346 shares during the last quarter. Meridian Wealth Management LLC purchased a new position in Edwards Lifesciences during the 3rd quarter valued at approximately $303,000. Finally, Larson Financial Group LLC increased its stake in Edwards Lifesciences by 199.1% in the 3rd quarter. Larson Financial Group LLC now owns 4,391 shares of the medical research company’s stock worth $290,000 after acquiring an additional 2,923 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.